"Cross-Priming" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Class I-restricted activation of CD8-POSITIVE LYMPHOCYTES resulting from ANTIGEN PRESENTATION of exogenous ANTIGENS (cross-presentation). This is in contrast to normal activation of these lymphocytes (direct-priming) which results from presentation of endogenous antigens.
| Descriptor ID |
D045142
|
| MeSH Number(s) |
G12.450.050.400.545.150 G12.565.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cross-Priming".
Below are MeSH descriptors whose meaning is more specific than "Cross-Priming".
This graph shows the total number of publications written about "Cross-Priming" by people in this website by year, and whether "Cross-Priming" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 1 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cross-Priming" by people in Profiles.
-
Lung cDC1 and cDC2 dendritic cells priming naive CD8+ T cells in situ prior to migration to draining lymph nodes. Cell Rep. 2023 10 31; 42(10):113299.
-
A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours. Nat Nanotechnol. 2021 12; 16(12):1394-1402.
-
Soluble N-Acetylgalactosamine-Modified Antigens Enhance Hepatocyte-Dependent Antigen Cross-Presentation and Result in Antigen-Specific CD8+ T Cell Tolerance Development. Front Immunol. 2021; 12:555095.
-
Persistent antigen exposure via the eryptotic pathway drives terminal T cell dysfunction. Sci Immunol. 2021 02 26; 6(56).
-
Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019 02; 566(7743):270-274.
-
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411.
-
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein a Signaling. Immunity. 2017 08 15; 47(2):363-373.e5.
-
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight. 2016 09 22; 1(15):e85955.
-
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. J Immunol. 2016 08 01; 197(3):953-61.
-
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.